Company intelligence / Profile preview

ISA Scientific

Oegstgeest, Netherlands

Ownership: Private
Development stage: Other

Overview

Clinical trials up to Phase II have demonstrated safety, tolerability, and clinical efficacy of SLP® compounds. ISA103 is in Phase 1b/2 for uveal melanoma targeting PRAME; ISA104 in Phase 1 for chronic Hepatitis B.[1][3][4]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Synthetic Long Peptide
Industry: Biotech

Beyond the preview

Go deeper on ISA Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISA Scientific.

Explore the full profile